Researchers at Colorado State University have published a study in the Journal of Psychopharmacology indicating that psilocybin significantly reduces fentanyl cravings in lab mice. The preclinical trial demonstrated a notable reduction in opioid-seeking behavior among female subjects after exposure to the psychedelic compound. Researchers also observed that the treatment did not induce anxiety-like behaviors—a common side effect of many current substance use disorder interventions.
While the findings point toward promising non-addictive therapeutic applications for psychedelics, the sex-specific nature of the results highlights the complexity of pharmacological treatments for opioid addiction. This research arrives amid a broader cultural and regulatory shift toward exploring alternative treatments for the ongoing opioid crisis, expanding the intersection of traditional cannabis businesses and the burgeoning functional mushroom sector. As state-level legislation increasingly opens doors to legal psychedelic research and therapeutic access, industry stakeholders are paying close attention to how these developments might intersect with existing dispensary models.
Medical cannabis operators, in particular, are evaluating the commercial viability of multi-substance wellness portfolios that include both cannabinoids and psilocybin products. Translating these preclinical murine trials into human clinical applications will take time, yet the trajectory suggests that functional wellness and harm-reduction therapies will play a larger role in alternative medicine markets. Retailers should monitor these regulatory and scientific milestones as consumer interest broadens beyond traditional cannabis flowers and concentrates into targeted mental health and addiction mitigation solutions.